Project Grant R01EB039787
- The National Institute of General Medical Sciences awarded Brigham & Womens Hospital Inc. $393,800 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop GLYCOPATCH, a multifunctional trauma adhesive for life-threatening visceral organ injuries. The award supports research into a pectin-based hydrogel sealant designed to stabilize traumatic wounds and deliver site-directed bioactives including procoagulants or antibiotics in resource-limited...
- The National Institute of Biomedical Imaging and Bioengineering awarded Tissuelock LLC $314,362 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop an antioxidative fiber mesh adhesive for preventing seroma and hematoma complications following abdominoplasty and large soft tissue surgeries. Seromas and hematomas occur in up to 20–30% of these procedures, leading to infection, delayed healing, repeat...
- The National Heart, Lung, and Blood Institute awarded Worcester Polytechnic Institute $532,935 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the endothelial glycocalyx in sepsis-induced coagulopathy. The research targets sepsis-associated coagulopathy, a condition characterized by uncontrolled thrombosis, large vessel occlusion, and stroke that resists traditional anticoagulation therapies. The project will examine how sepsis...
- Arizona State University received a $428,022 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) effective August 1, 2025 through July 31, 2027. The research initiative focuses on the engineering and development of SEROGRAFT, a novel bio-inspired acellular biomaterial designed to prevent postoperative abdominal adhesions. SEROGRAFT is a...
- The National Institute of Biomedical Imaging and Bioengineering awarded The General Hospital Corporation (Massachusetts General Hospital) $206,250 on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and evaluate the feasibility of an integrated mechano-arthroscope for minimally invasive assessment of joint tissue pathology and micromechanics. The project addresses a gap in arthritis diagnosis: current...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $539,066 to Massachusetts General Hospital (The General Hospital Corporation, Research Management Division) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating the role of microglial extracellular vesicles in the progression of atherosclerosis following traumatic brain injury. The...
- The National Institute of General Medical Sciences (part of the National Institutes of Health, Department of Health and Human Services) awarded $393,800 to the Terasaki Institute for Biomedical Innovation on September 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop immunomodulatory nanofibrous modular aerogels for chronic wound healing. The research addresses chronic wounds affecting approximately 6.5 million Americans by combining three engineered...
- The National Institute of Biomedical Imaging and Bioengineering awarded $318,676 to Massachusetts General Hospital on February 13, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and validate a microfluidic chip technology for high-throughput loading of cryoprotective agents into therapeutic allogeneic immune cells. The project, titled VELCPA (Veloporation for CPA Loading), addresses cell cryopreservation...
- The National Institute of Biomedical Imaging and Bioengineering awarded Colorado State University $231,000 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to optimize hemocompatible extracorporeal membrane oxygenation (ECMO) membranes through biomimetic surface modification and computational fluid dynamics. The research addresses blood clotting and platelet loss in hollow fiber membrane oxygenators used in...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $473,937 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, for a project period extending through June 30, 2027. The award supports development of a novel point-of-care liquid biopsy diagnostic tool for early detection of sepsis-associated organ damage. The project leverages the institution's pioneering liquid biopsy...
The National Institute of Biomedical Imaging and Bioengineering, part of the Department of Health and Human Services National Institutes of Health, awarded Massachusetts General Hospital $2,007,744 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop MSEAL, a supramolecular surgical sealant for hemostasis in burn excision surgery. MSEAL is a spray-on, highly adhesive sealant engineered to address massive blood loss during deep partial-thickness and full-thickness burn excision and grafting. The sealant combines rapid gelation on large wound areas, strong wet-tissue adhesion, hemostatic nanofillers to accelerate clotting, and on-demand dissolution to enable subsequent skin graft placement. Current surgical approaches, including tourniquets, vasoconstrictors, and transfusion, remain inadequate; excision of 20 percent total body surface area routinely results in 3,500 to 8,000 milliliters of blood loss requiring 7 to 16 units of transfused blood, with excessive bleeding associated with a fourfold increase in mortality. The research spans four years, concluding August 31, 2030, and is performed in Boston, Massachusetts. Specific Aim 1 designs and optimizes supramolecular sealants and characterizes their properties. Specific Aim 2 assesses hemostatic, mechanical, and biocompatibility outcomes in vitro. Specific Aim 3 evaluates in vivo efficacy and safety of MSEAL in a swine burn excision model.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.0m | 8/5/26 |